Noile-Immune Biotech Inc. (TYO:4893)

Market Cap	6.45B -20.7%
Revenue (ttm)	7.00M -97.8%
Net Income	-782.00M
EPS	-18.06
Shares Out	43.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,700
Average Volume	138,270
Open	150.00
Previous Close	152.00
Day's Range	146.00 - 151.00
52-Week Range	120.00 - 214.00
Beta	-0.50
RSI	53.05
Earnings Date	Feb 13, 2026

About Noile-Immune Biotech

Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company’s product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, an autologous CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 25
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4893

Financial Performance

In 2024, Noile-Immune Biotech's revenue was 7.00 million, a decrease of -97.78% compared to the previous year's 316.00 million. Losses were -964.00 million, -14.69% less than in 2023.